IMW 2021 | MRD in myeloma: the patient perspective
Lanny Kirsch
• 9 Sep 2021
Lanny Kirsch, MD, Adaptive Biotechnologies, Seattle, WA, talks on the patient perspective on measurable residual disease (MRD) in myeloma, talking on reports from patient advocacy groups. Dr Kirsch explains how knowing that a tool as sensitive as MRD is available can be of comfort to patients. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Lanny Kirsch, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.
